Table 1 Characteristics of studies included in the systematic review
Study | Year | Country | Follow-up | Patients enrolled (n) LMWH/UFH (n/n) | Drop-outs (n) LMWH/UFH (n/n) | LMWH type | LMWH mean dose | UFH mean dose | HD/HDF |
|---|---|---|---|---|---|---|---|---|---|
Cross-over randomized design | |||||||||
Cianciolo et al. [16] | 2011 | Italy | 2 months | 40 | 0 | Nadroparin | 64 IU/kg | bolus 50 IU/kg and 30 IU/kg/h | HD |
Klejna et al. [29] | 2014 | Poland | 6 months | 21 | 0 | Enoxaparin | 5280 IU ± 1120 IU | 4881 IU ± 1916.3 IU | HD |
Lord et al. [22] | 2002 | Canada | 2 months | 32 | 2 | Tinzaparin | 4318.2 IU ± 702.8 IU | 8207.9 IU ± 2530.9 IU | HD |
Saltissi et al. [24] | 1999 | Australia | 6 months | 36 | 5 | Enoxaparin | 100 IU/kg | bolus 50 IU/kg and 1000 IU/h | HD |
Stefoni et al. [27] | 2002 | Italy | 36 months | 54 | 7 | Nadroparin | 64 IU/kg | bolus 1500 IU and 1500 IU and 1500 IU ± 500 IU perfusion | HDF |
Cross-over non-randomized design | |||||||||
Al-Saran et al. [13] | 2010 | Saudi Arabia | 12 months | 23 | 0 | Tinzaparin | 2000–3000 IU | 5000 IU | HD |
Bambauer et al. [14] | 1990 | Germany | 12 months | 27 | 6 | Dalteparin | 4216 IU ± 2237 IU | 4958 IU ± 2561 IU | HD |
Bramham et al. [15] | 2008 | United Kingdom | 4 months | 110 | 2 | Tinzaparin | 2500–5000 IU | 1000 IU ± 500–2000 IU | HDF |
Deuber et al. (part 1) [17] | 1991 | Germany | 60 months | 5 | 0 | Non specified | Non specified | 29–143 IU/kg | HD |
Deuber et al. (part 2) [17] | 1991 | Germany | 24 months | 5 | 0 | Non specified | Non specified | 29–143 IU/kg | HD |
Kronenberg et al. [19] | 1995 | Austria | 12 months | 24 | 0 | Certoparin | 44.7 IU/kg ± 21.5 IU/kg | 25.1 IU/kg ± 7.8 IU/kg | HD |
Lai et al. [20] | 2001 | China | 24 months | 40 | 6 | Nadroparin | 4100–6150 IU | 5000–7000 IU | HD |
Leu et al. [21] | 1998 | Taiwan | 4 months | 20 | 0 | Dalteparin | 2413 IU ± 954 IU | 2413 IU ± 954 IU | HD |
Schmitt et al. [25] | 1993 | Germany | 12 months | 22 | 0 | Dalteparin | bolus 1500 IU and 675 IU/h ± 284 IU/h | bolus 1500 IU and 1031 IU/h ± 342 IU/h | HD |
Yang et al. (part 1) [28] | 1998 | Taiwan | 1 month | 10 | 0 | Fraxiparin | 10,000 ICU | bolus 1800 IU ± 675 IU and 895 IU/h ± 340 IU/h | HD |
Yang et al. (part 2) [28] | 1998 | Taiwan | 12 months | 10 | 2 | Fraxiparin | 192.9 ICU/kg ± 3.8 ICU/kg | bolus 1800 IU ± 675 IU and 895 IU/h ± 340 IU/h | HD |
Randomized parallel design | |||||||||
Elisaf et al. [18] | 1997 | Greece | 12 months | 76 38/38 | 0 | Tinzaparin | 3000 IU | 5000–7000 IU | HD |
Nurmohamed et al. [23] | 1991 | The Netherlands | 6 months | 70 35/35 | 13 8/5 | Nadroparin | 150–200 IU/kg | bolus 2500 IU and 600–2200 IU/h | HD |
Schrader et al. [26] | 1988 | Germany | 12 months | 70 35/35 | 8 5/3 | Dalteparin | bolus 36.8 IU/kg ± 17.3 IU/kg and 12.2 IU/kg/h ± 5.0 IU/kg/h | bolus 58.3 IU/kg ± 26.3 IU/kg and 16.6 IU/kg/h ± 6.7 IU/kg/h | HDF |